1100241

Celgene Corporation — FEI 3004991673

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
July 26, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Summit, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)